Children’s Hospital Los Angeles Offers MIBG Therapy for Neuroblastoma

Children with high-risk neuroblastoma can now access a specialized, targeted radiation treatment called MIBG therapy at Children’s Hospital Los Angeles—one of the largest neuroblastoma programs in the country and the only pediatric facility in Southern California and the Southwestern United States to offer this treatment.

CHOP Researchers Develop a New Class of CAR-T Cells that Target Previously Untargetable Cancer Drivers

In a breakthrough for the treatment of aggressive solid cancers, researchers at Children’s Hospital of Philadelphia (CHOP) have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach. Using the power of large data sets and advanced computational approaches, the researchers were able to identify peptides that are presented on the surface of tumor cells and can be targeted with “peptide-centric” chimeric antigen receptors (PC-CARs), a new class of engineered T cells, stimulating an immune response that eradicates tumors.

Are childhood cancers different? Understanding the immune response to tumors in pediatric neuroblastoma

UChicago Medicine physician-scientists aimed to find out how the immune systems of children with a type of cancer called neuroblastoma respond to tumors. The answer to this question could help guide the treatment of pediatric patients.

Researchers identify gene implicated in neuroblastoma, a childhood cancer

A new study by Mayo Clinic researchers has identified that a chromosome instability gene, USP24, is frequently missing in pediatric patients with neuroblastoma, an aggressive form of childhood cancer. The finding provides important insight into the development of this disease. The study is published in Cancer Research, the journal of the American Association for Cancer Research.

Algorithm Reduces Need for Therapy in Children With Intermediate-Risk Neuroblastoma

Roswell Park’s Dr. Clare Twist led an effort to develop and validate a new treatment algorithm for infants and children with neuroblastoma. In a new study in the Journal of Clinical Oncology, the team reports that many patients can safely receive less extensive therapy.